A STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER [IMaGYN050]

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223474

Enrollment

1300

Registered

2017-03-08

Start date

2017-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Interventions

investigational material(s) Generic name etc : Atezolizumab INN of investigational material : atezolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investig

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: -Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC),peritoneal primary carcinoma, or fallopian tube cancer -Eastern Cooperative Oncology Group (ECOG) performance status of 0,1,or 2 -Life expectancy greater than (>) 12 weeks -Adequate hematologic and end organ function -For participants who receive therapeutic anticoagulation:stable anticoagulant regimen

Exclusion criteria

Exclusion criteria: -Received a current diagnosis of tumors of low malignant potential (borderline epithelial ovarian cancer), or non-epithelial ovarian tumors -Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer -Other invasive malignancies with any evidence of other cancers present within the last 5 years with the exception of other specific malignancies(e.g. localized breast cancer) -Pregnant or lactating women -History of autoimmune disease -Have a positive test result for HIV, active hepatitis B or hepatitis C infection -Significant cardiovascular disease -Prior treatment with CD137 agonists or immune checkpoint blockade therapies,anti-PD1,anti-PD-L1,or anti-CTLA4 therapeutic antibody

Design outcomes

Primary

Measure	Time frame
efficacy Progression-Free survival, Overall survival RECIST v1.1, Observation	—

Secondary

Measure	Time frame
safety efficacy Objective response rate, Safety, etc. RECIST v1.1, Observation, etc.	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania, Russian Federation, South America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026